Phase 1 Study to Evaluate MEDI4736
NCT ID: NCT02117219
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 14-115
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 in subjects with myelodysplastic syndrome.
Dana-Farber Cancer Institute, Brigham and Women's Hospital
Robert Coleman Lindsley, MD, PhD,
Dana Farber Cancer Institute
Dana-Farber Cancer Institute:
Ilene Galinsky, 617-632-3902,
Adult male or female subjects with pathologically confirmed MDS who failed to respond,
relapsed after an initial response, or were unable to tolerate hypomethylating agents,
ECOG performance status of 0 - 2, and adequate organ and marrow function.
Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
treatment, prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical
transplant, current immunosuppressive medication or autoimmune or inflammatory disease.